United Kingdom

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Astrazeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford’s Potential New Vaccine

Lead Product(s): AZD1222

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: BARDA

Deal Size: $1,000.0 million Upfront Cash: Undisclosed

Deal Type: Funding May 21, 2020

Details:

The Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Astrazeneca Gets Funding And Manufacturing Boost For UK Vaccine Programme

Lead Product(s): ChAdOx1 nCoV-19

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $81.3 million Upfront Cash: Undisclosed

Deal Type: Funding May 17, 2020

Details:

The Government has announced £65.5 million of new funding for the vaccine being developed at the Oxford Vaccine Group as coronavirus vaccine trials accelerate. If the Oxford vaccine is successful, AstraZeneca will deliver 100 million doses in total worldwide.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Astrazeneca Strikes Deal With Oxford University to Mass Produce Experimental COVID-19 Vaccine

Lead Product(s): ChAdOx1 nCoV-19

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Oxford University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 30, 2020

Details:

The collaboration aims at bringing to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

AstraZeneca PLC

Astrazeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford’s Potential New Vaccine

AstraZeneca PLC

Astrazeneca Gets Funding And Manufacturing Boost For UK Vaccine Programme

AstraZeneca PLC

Astrazeneca Strikes Deal With Oxford University to Mass Produce Experimental COVID-19 Vaccine